Accessibility Menu
BioMarin Pharmaceutical Stock Quote

BioMarin Pharmaceutical (NASDAQ: BMRN)

$53.77
(1.3%)
+0.70
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$53.77
Daily Change
(1.3%) +$0.70
Day's Range
$52.63 - $53.97
Previous Close
$53.77
Open
$53.09
Beta
0.75
Volume
88,314
Average Volume
2,171,432
Market Cap
10.2B
Market Cap / Employee
$53.07M
52wk Range
$51.57 - $73.51
Revenue
-
Gross Margin
0.79%
Dividend Yield
N/A
EPS
$3.38
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

BioMarin Pharmaceutical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
BMRN-23.43%-32.03%-7.43%+304%
S&P+14.84%+96.04%+14.41%+396%

BioMarin Pharmaceutical Company Info

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

News & Analysis

The Fool has written over 200 articles on BioMarin Pharmaceutical.

Financial Health

General

Q2 2025YOY Change
Revenue$827.47M16.8%
Gross Profit$672.54M19.3%
Gross Margin81.28%1.7%
Market Cap$10.54B-32.6%
Market Cap / Employee$3.47M0.0%
Employees3K-10.6%
Net Income$240.53M124.4%
EBITDA$320.07M146.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.21B24.9%
Accounts Receivable$855.86M23.8%
Inventory1.3K13.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$596.16M0.3%
Short Term Debt$15.72M-96.9%

Ratios

Q2 2025YOY Change
Return On Assets9.05%5.3%
Return On Invested Capital5.50%1.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$168.17M72.6%
Operating Free Cash Flow$185.27M56.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings42.3229.8926.2316.28-73.81%
Price to Book2.532.312.381.82-40.92%
Price to Sales5.044.554.753.56-44.09%
Price to Tangible Book Value2.772.532.631.97-42.02%
Price to Free Cash Flow TTM43.3226.5122.2515.59-78.20%
Enterprise Value to EBITDA78.2276.8852.2831.29-75.19%
Free Cash Flow Yield2.3%3.8%4.5%6.4%358.80%
Return on Equity6.3%8.0%9.6%11.6%127.97%
Total Debt$610.18M$649.47M$609.82M$611.88M-44.36%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.